ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Extended Oral Glucose Tolerance Test Unmasks Intermediate Metabolic Phenotypes in Polycystic Ovary Syndrome.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the efficacy of an extended oral glucose tolerance test (OGTT) incorporating 1- and 3-h time points in detecting early, heterogeneous glycemic phenotypes in polycystic ovary syndrome (PCOS). Methods: In this cross-sectional study, 103 treatment-naive patients with PCOS underwent a 75-g OGTT with measurements of glucose and insulin taken at 0, 1, 2, and 3 h. Participants were stratified into four groups: normal control, isolated 1-h glucose elevation (1-h plasma glucose [PG] ≥ 8.6 mmol/L), isolated 3-h glucose elevation (3-h PG > 6.1 mmol/L), and dysglycemia defined by conventional criteria. Comprehensive metabolic and endocrine profiles were evaluated and compared. Results: Two distinct early glycemic phenotypes were identified: isolated 1-h glucose elevation (13.6%, 14/103) and isolated 3-h glucose elevation (20.4%, 21/103). The isolated 3-h elevation group exhibited an intermediate phenotype characterized by significant central adiposity, hyperandrogenism, and menstrual irregularities, despite systemic insulin resistance (IR) levels comparable to those of the normoglycemic group. Conversely, the isolated 1-h elevation group exhibited transient hyperinsulinemic hyperglycemia and elevated low-density lipoprotein cholesterol (LDL-C) levels. Both phenotypes were undetected by standard glycemic criteria. Conclusion: An extended OGTT reveals two prevalent yet distinct early glycemic phenotypes in PCOS, suggesting heterogeneous pathophysiological pathways that may inform dynamic, phenotype-stratified assessment for risk stratification and targeted intervention. However, clinical implementation requires validation through prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.